Details of the Drug Reposition

General Information of This Drug (ID: DMQOXNL)

Drug Name
LMB763   DMQOXNL
Synonyms
Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-alcoholic steatohepatitis DIST4788 DB92.1 Phase 2 [1]
Diabetic nephropathy DIS2FCCT GB61.Z Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02913105) Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03804879) Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy. U.S. National Institutes of Health.